TTLL13 activators belong to a chemical class designed to interact with the enzyme known as tubulin tyrosine ligase-like 13 (TTLL13). This enzyme is part of the TTLL family, which plays a crucial role in the post-translational modification of proteins, specifically through the process of glutamylation. Glutamylation is a type of modification where glutamate residues are added to target proteins, affecting their function and interactions. TTLL13 has been identified as one of the enzymes that catalyze this modification on tubulins and potentially other proteins. Tubulins are the building blocks of microtubules, which are critical components of the cellular cytoskeleton. The cytoskeleton provides structure to the cell, and microtubules are particularly important for cell division, intracellular transport, and the maintenance of cell shape.
Activators in the TTLL13 class are designed to increase the enzymatic activity of TTLL13. By doing so, they enhance the glutamylation process, which in turn can have significant effects on the microtubule network within cells. The fine-tuning of microtubule dynamics and functions is crucial for the proper execution of various cellular processes. The chemical structure of TTLL13 activators is often tailored to fit within the active site of the TTLL13 enzyme or to interact with regions of the enzyme that can modulate its activity. This specific interaction ensures that the effect of these activators is targeted, aiming to achieve an upregulated enzymatic function. The increased activity of TTLL13 can result in a higher degree of glutamylation, which can affect many aspects of cellular function due to the pivotal role of tubulins and the microtubule network. Understanding and manipulating these molecular interactions is a fundamental aspect of chemical biology and protein chemistry.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly increases intracellular cAMP, which in turn can activate PKA. PKA phosphorylation can enhance TTLL13 activity by promoting its functional role in protein modification. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, leading to an increase in cAMP levels. Elevated cAMP can enhance TTLL13 activity through PKA activation. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective phosphodiesterase-4 inhibitor, causing an increase in cAMP, potentially enhancing TTLL13 activity through cAMP-dependent pathways. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
Cilostazol is a phosphodiesterase-3 inhibitor, increasing cAMP levels and potentially enhancing TTLL13 activity via PKA activation. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic Acid is a potent inhibitor of protein phosphatases PP1 and PP2A, leading to increased phosphorylation levels of proteins, which could indirectly enhance the activity of TTLL13. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Like Okadaic Acid, Calyculin A inhibits protein phosphatases leading to increased phosphorylation which could enhance TTLL13 activity indirectly through phosphorylation signaling. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a PKC activator, and PKC-mediated signaling pathways can lead to phosphorylation which may indirectly enhance TTLL13 activity. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that also activates MAPK signaling pathways. MAPK activation can lead to enhanced TTLL13 activity through downstream signaling effects. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is a selective inhibitor of phosphodiesterases, particularly PDE5, which increases cGMP levels, potentially enhancing TTLL13 activity through cGMP-dependent signaling pathways. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine is a phosphodiesterase-1 inhibitor, which increases cAMP and cGMP levels, potentially enhancing TTLL13 activity through cAMP/cGMP-dependent signaling pathways. | ||||||